Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Three Xarelto Wrongful Death Lawsuits Recently Filed, Notes The Cochran Firm, D.C.
  • USA - English


News provided by

The Cochran Firm, D.C.

Sep 26, 2014, 04:00 ET

Share this article

Share toX

Share this article

Share toX

(PRWEB) September 26, 2014 -- According to lawsuits filed in federal courts in New York, Florida, and Vermont within the last three months, family members of individuals who took the blood thinner drug Xarelto have filed wrongful death lawsuits, claiming that Xarelto allegedly caused irreversible and life-threatening bleeding. In the U.S. District Court for the Eastern District of New York (Case 1:14-cv-04841-FB-VMS), a lawsuit filed on Aug. 14 asserts that the anticoagulant drug Xarelto allegedly caused fatal and irreversible bleeding.

Another Xarelto lawsuit filed on June 23 in the U.S. District Court for the Southern District of Florida (Case 0:14-cv-61448-JAL) alleges that the blood thinner drug caused a fatal, subdural hemorrhage. A lawsuit filed in the U.S. District Court for the District of Vermont (Case 2:14-cv-00159-cr) on July 25 by the family of a deceased individual who used Xeralto alleges that the drug caused life-threatening, irreversible bleeding, which allegedly cumulated in his premature death.

“These wrongful death lawsuits make serious allegations about popular blood thinner drug Xeralto. In response to these and other legal actions, our team of injury attorneys are conducting a vigorous investigation regarding alleged Xarelto injuries and whether the drug contained adequate warnings, whether the drug’s benefits justified the risks, and other issues,” David Haynes, managing attorney of The Cochran Firm, D.C., said. “I encourage anyone who may have suffered Xarelto injuries to give The Cochran Firm a call at 1-800-THE-FIRM or contact us on the Web at http://www.cochranfirmdc.com. We are investigating claims nationwide from individuals who took Xarelto and family members of individuals who died after taking Xarelto.”

Product liability and injury attorneys with The Cochran Firm, D.C. have launched an investigation into bleeding injuries alleged to be associated with the blood thinner Xarelto (rivaroxaban). The law firm’s attorneys are interviewing individuals who allegedly suffered severe Xarelto side effects and evaluating claims for potential compensation.

The U.S. Food and Drug Administration approved the anticoagulant Xarelto between November 2011 and November 2012 to prevent pulmonary embolisms, deep vein thrombosis, and strokes in hip and knee replacement patients and individuals suffering non-valvular atrial fibrillation. Xarelto was developed by Bayer and Johnson & Johnson’s subsidiary Janssen Pharmaceuticals. Xarelto has been marketed as a replacement for Coumadin (warfarin), which is the standard anticoagulant, because Xarelto requires less monitoring.

The three Xarelto lawsuits make many allegations against the makers of the blood thinner drug, Johnson & Johnson, Bayer, and Janssen Pharmaceuticals, including:

  • Alleged negligence in failing to ensure Xarelto would not cause users allegedly unreasonable, dangerous side effects
  • Manufacturing, producing, promoting, and/or designing a product allegedly unsafe, dangerous, or non-compliant with FDA regulations
  • Product liability for making, testing, advertising, promoting, marketing, selling, and distributing an allegedly unreasonably dangerous drug
  • Breach of warranty for allegedly representing that Xarelto is safe and does not contain numerous allegedly serious side effects
  • Alleged fraudulent misrepresentation for allegedly representing that Xarelto was safe and/or effective
  • Alleged fraudulent concealment for hiding Xarelto’s allegedly dangerous side effects
  • Alleged negligent misrepresentation for allegedly failing to exercise ordinary care in the making, manufacturing, testing, selling, quality control, and distribution of Xarelto
  • Alleged violations of consumer protection laws
  • Wrongful death claims by family members of individuals who died after taking Xarelto

Due to the serious allegations raised against the makers of Xarelto, The Cochran Firm, D.C. is offering a free consultation and case review for individuals who allegedly suffered serious Xarelto side effects and family members of those who died after taking Xarelto.

About The Cochran Firm
With decades of collective legal experience, the team of seasoned attorneys at The Cochran Firm represents victims of catastrophic personal injury, medical malpractice, defective products, and class action members in the Baltimore, Maryland and Washington, D.C. metropolitan regions and nationwide. The qualified legal professionals with The Cochran Firm bring experienced, high-caliber legal expertise to ordinary citizens who have been injured by others’ careless actions. Attorneys with The Cochran Firm were selected as 2013 and 2014 Super Lawyers, Best Lawyers in America, and have received top ratings from their peers, local and national publications and organizations, and clients for achieving successful verdicts and settlements for injury victims.

Consultations with The Cochran Firm, D.C.’s attorneys are confidential and carry no obligation.

Will Atkinson, The Cochran Firm, D.C., http://www.CochranFirmDC.com, +1 202-682-5800, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.